FDA Issues New Vision Loss Warning for Ozempic, Wegovy, and Other GLP-1 Medications

Popular medications used to treat diabetes and support weight loss are receiving a new warning about a rare but potentially serious eye condition.
 

On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced that manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, must add warnings about a possible increased risk of sudden vision loss.
 

The concern involves a condition called non-arteritic anterior ischemic optic neuropathy (NAION), which affects blood flow to the optic nerve and can cause permanent vision loss.
 

Although the risk appears to be very low, the announcement highlights the importance of recognizing sudden vision changes and understanding how certain medications may affect eye health.

What Are GLP-1 Medications?

GLP-1 medications have become increasingly common for managing type 2 diabetes and obesity.
 

These medications work by mimicking hormones that help regulate blood sugar, appetite, and digestion.
 

Common medications in this category include:

• Ozempic (semaglutide)

• Wegovy (semaglutide)

• Rybelsus (semaglutide)

• Mounjaro (tirzepatide)

• Zepbound (tirzepatide)

• Trulicity (dulaglutide)

• Victoza (liraglutide)
   

These medications can provide significant health benefits, including improved blood sugar management and weight reduction. Some also have demonstrated cardiovascular and kidney benefits in appropriate patients.
 

However, as their use has increased, researchers have continued investigating potential side effects, including their effects on the eyes.

What Is NAION?

Non-arteritic anterior ischemic optic neuropathy, commonly called NAION, is a condition that occurs when blood flow to the front portion of the optic nerve becomes insufficient.
 

The optic nerve carries visual information from the eye to the brain. When its blood supply is disrupted, damage can occur, sometimes resulting in permanent vision loss.
 

NAION typically causes sudden, painless vision loss in one eye.
 

Symptoms may include:

• Sudden blurred or decreased vision

• A dark or missing area in the visual field

• Loss of part of the upper or lower visual field

• Reduced central vision

• Changes in color perception
   

Symptoms are sometimes first noticed upon waking in the morning.
 

Unlike temporary blurry vision associated with blood sugar fluctuations, vision loss caused by NAION may be permanent.
 

Any sudden loss of vision requires immediate medical evaluation, even if there is no pain.

What Did the FDA Find?

The FDA reviewed clinical trials, observational studies, and reports of vision problems in patients taking GLP-1 medications.

In an analysis of 126 randomized clinical trials involving more than 134,000 participants, researchers identified a small number of NAION cases.
 

The reported incidence was:

• 6.4 cases per 100,000 person-years among patients taking GLP-1 medications

• 3.8 cases per 100,000 person-years among patients receiving placebo or other comparison medications
   

These findings suggest a possible increased risk, although the condition remains rare.
 

The FDA also reviewed real-world patient data and published studies. Some studies found an association between GLP-1 medications and NAION, while others produced less conclusive results.
 

Because patients taking these medications often have diabetes, obesity, or other vascular risk factors, determining whether the medications directly cause NAION is challenging.
 

The FDA concluded that the available evidence supports adding a warning about a potential increased risk, but the precise relationship remains under investigation.

Who Is at Greater Risk for NAION?

NAION can occur in individuals who have never taken GLP-1 medications.
 

Several medical conditions and lifestyle factors have been associated with an increased risk, including:

• Diabetes

• High blood pressure

• Obstructive sleep apnea

• Smoking

• Kidney disease

• Anemia

• Certain optic nerve anatomical characteristics
   

Patients who have previously experienced NAION in one eye also have an increased risk of developing the condition in the other eye.
 

Because many of these risk factors overlap with the conditions GLP-1 medications are prescribed to treat, evaluating an individual's overall risk is important.

Should You Stop Taking Ozempic or Other GLP-1 Medications?

For most patients, the FDA announcement does not mean they should stop taking their medication.
 

GLP-1 medications can provide substantial benefits for patients with diabetes, obesity, and certain cardiovascular conditions.
 

The potential risk of NAION appears to be small, and abruptly discontinuing treatment without medical guidance could interfere with management of an underlying health condition.
 

Patients should discuss any concerns with the healthcare professional who prescribes their medication.
 

If NAION develops, the prescribing clinician and eye specialist should reassess whether continuing the medication is appropriate.

What Should You Do if You Notice Sudden Vision Changes?

Sudden vision loss should always be treated as a medical emergency.
 

If you experience sudden blurred vision, a missing area of vision, or significant vision loss in one eye, seek immediate emergency medical evaluation.
 

Do not wait to see whether the symptoms improve or assume they are a normal medication side effect.
 

These symptoms can occur with several serious eye and neurological conditions, including retinal artery occlusion, retinal detachment, and optic nerve disorders.
 

Prompt evaluation is essential to determine the cause and identify conditions that may require immediate treatment.

Why Regular Eye Exams Are Important

Comprehensive eye examinations play an important role in monitoring eye health, particularly for patients with diabetes, high blood pressure, or other vascular risk factors.
 

At Eyes & Optics, our doctors evaluate the health of the retina and optic nerves using comprehensive examination techniques and advanced imaging when appropriate.
 

These evaluations can help identify diabetic eye disease, glaucoma, and certain optic nerve abnormalities.
 

However, routine eye examinations cannot reliably predict or prevent NAION. The most important precaution is recognizing sudden vision changes and seeking immediate medical attention.
 

Patients taking GLP-1 medications should inform their eye doctor about their medications and any changes in their medical history.

Protecting Your Vision at Eyes & Optics

The FDA's new warning is an important reminder that medications used to improve overall health can sometimes have effects on the eyes.
 

For most patients, GLP-1 medications continue to offer meaningful health benefits, and the risk of NAION remains rare.
 

At Eyes & Optics, our doctors provide comprehensive eye examinations for patients with diabetes and other medical conditions that may affect eye health.
 

If you take Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication, we encourage you to discuss your medical history and any visual concerns during your next eye examination.
 

Call Eyes & Optics at 248-788-1610 or visit eyesandoptics.com to schedule an appointment.
 

At Eyes & Optics, we're proud to provide personalized eye care for individuals and families in Farmington, Farmington Hills, Novi, Commerce Township, West Bloomfield, Walled Lake, Livonia, Northville, Orchard Lake, Plymouth, Wixom and surrounding Metro Detroit communities.

Sources

1. U.S. Food and Drug Administration. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition. November 9, 2026.

2. The Washington Post. FDA Tells GLP-1 Makers to Warn of Potential Vision Loss Side Effect. November 9, 2026.

3. Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024;142(8):732–739.